65,437 trials
Alzheimer's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 3; 9; 5 participants
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Smoking Lapse Behavior
Primary: Latency to Initiate Ad-lib Smoking Session — 38.138; 39.416; 19.249 minutes
Metastatic Renal Cell Carcinoma
Primary: Response Rate — 0 percentage of participants
Chronic Pain
Primary: Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment — 40.91; 30.16 percentage of participants
Colitis, Ulcerative · Inflammatory Bowel Diseases · Crohn's Disease
Primary: Mortality Rate — 21.4; 30.1 events per 1000 person-years
Multiple Myeloma
Primary: Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr — 28; 1 Participants — p=<0.05
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 327.08; 1903.61 pg/mg creat — p=<.001
Systemic Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation…
Laceration · Anxiety
Primary: mYPAS Score as Completed by Researchers to Assess Anxiety — 23.3; 36.3 units on a scale
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
Recurrent Extragonadal Seminoma · Recurrent Malignant Extragonadal Germ Cell Tumor · Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
Primary: Objective Response Rate — 0; 6; 2; 10 participants
Diabetes Mellitus, Type 2, Cancer
Primary: Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status — 380.2; 421.9; 308.0; 281.9 Incidence per 100,000 person-years
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Adult Acute Myeloid Leukemia
Primary: Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD — 5.7 percentage of participants